Cancer starvation therapy
AssigneeSerbig Pharmaceuticals Corp.
InventorPedro Anastacio Serrano-Ojeda
Life of this patent
Estimating the term…
Abstract
The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
Claims2
A method for treating tumorigenic cells by targeting the cells mitochondria comprising:
- treating the tumorigenic cells with a radiosensitizing containing glutamine-ligand-high Z element compound and also treating the tumorigenic cells with a high energy radiation,
- wherein the glutamine-ligand-high Z element compound is selected from the group consisting of the compounds having the Formula IB, IIA, IIB, IIIA, IIIB, IVA, IVB, VA or VB;
- wherein m=1-50 (1-5, 1-10) and wherein Z is iodine
Dependencies are inferred from the claim text.